BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35217626)

  • 1. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.
    Ren Z; Kim A; Huang YT; Pi WC; Gong W; Yu X; Qi J; Jin J; Cai L; Roeder RG; Chen WY; Wang GG
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated regulation of retinoic acid signaling pathway by KDM5B and polycomb repressive complex 2.
    Zhang Y; Liang J; Li Q
    J Cell Biochem; 2014 Sep; 115(9):1528-38. PubMed ID: 24619877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis.
    Huang J; Jin S; Guo R; Wu W; Yang C; Qin Y; Chen Q; He X; Qu J; Yang Z
    RNA; 2024 Mar; 30(4):435-447. PubMed ID: 38296629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
    Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
    Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
    Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
    Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
    Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
    Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
    Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
    Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
    Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
    Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
    J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal.
    Hunkapiller J; Shen Y; Diaz A; Cagney G; McCleary D; Ramalho-Santos M; Krogan N; Ren B; Song JS; Reiter JF
    PLoS Genet; 2012; 8(3):e1002576. PubMed ID: 22438827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
    Bueno MT; Richard S
    Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone demethylase KDM5B for cancer treatment.
    Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
    Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
    Hayami S; Yoshimatsu M; Veerakumarasivam A; Unoki M; Iwai Y; Tsunoda T; Field HI; Kelly JD; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
    Mol Cancer; 2010 Mar; 9():59. PubMed ID: 20226085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
    Ren Z; Ahn JH; Liu H; Tsai YH; Bhanu NV; Koss B; Allison DF; Ma A; Storey AJ; Wang P; Mackintosh SG; Edmondson RD; Groen RWJ; Martens AC; Garcia BA; Tackett AJ; Jin J; Cai L; Zheng D; Wang GG
    Blood; 2019 Oct; 134(14):1176-1189. PubMed ID: 31383640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
    Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
    Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
    Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
    Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
    Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
    Shi J; Wang E; Zuber J; Rappaport A; Taylor M; Johns C; Lowe SW; Vakoc CR
    Oncogene; 2013 Feb; 32(7):930-8. PubMed ID: 22469984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.